TIME TO BE
EPCLUSA was the first Hep C therapy proven to effectively treat all six main Hep C genotypes with a simple one-pill, once-a-day treatment regimen for the majority of patients.*
In clinical studies, EPCLUSA had a high overall cure rate of 98% in patients with genotypes 1–6.†
Cure means the Hep C virus is not detected in the blood when measured three months after treatment is completed.
SCROLL TO FIND OUT IF IT’S YOUR TIME
EPCLUSA is a prescription medicine used to treat adults with chronic hepatitis C genotypes 1–6 infection without cirrhosis or with compensated cirrhosis.
*EPCLUSA with ribavirin is recommended for patients with advanced cirrhosis (decompensated).‡ If you take EPCLUSA with ribavirin, you should also read the ribavirin Medication Guide for important pregnancy-related information.
†In three separate clinical studies with a combined total of 1558 patients with genotype 1–6 Hep C, with or without prior Hep C treatment, and with or without cirrhosis (compensated), who received either EPCLUSA or placebo for 12 weeks, 98% (1015/1035) of all patients who received EPCLUSA once daily for 12 weeks were cured.
These studies did not include patients with advanced cirrhosis (decompensated).‡
‡Advanced cirrhosis (decompensated) is when the liver is extensively scarred and can no longer do its job effectively.
EPCLUSA is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype 1, 2, 3, 4, 5, or 6 infection with or without cirrhosis (compensated). In those with advanced cirrhosis (decompensated), EPCLUSA is used with ribavirin.
What is the most important information I should know about EPCLUSA?
EPCLUSA can cause serious side effects, including:
- Hepatitis B virus reactivation: Before starting EPCLUSA treatment, your healthcare provider will do blood tests to check for hepatitis B infection. If you have ever had hepatitis B, the hepatitis B virus could become active again during and after treatment with EPCLUSA. This may cause serious liver problems including liver failure and death. If you are at risk, your healthcare provider will monitor you during and after taking EPCLUSA.